ADAM17 (disintegrin and metalloproteinase domain-containing protein 17) cleaves the membrane bound precusor of TNF-alpha to its mature soluble form. ADAM 17 is responsbile for the proteolytical release of soluble JAM3 from endothelial cells surface and the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1, and the amyloid precursor protein. It acts as an activator of the Notch pathway by mediating cleavage of Notch and generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Mutations in the gene can result in inflammatory skin and bowel disease, neonatal 1.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: a disintegrin and metalloproteinase; ADAM; ADAM 17; ADAM metallopeptidase domain 18; ADAMs; CD156b; CD156b antigen; Disintegrin and metalloproteinase domain-containing protein 17; metalloendopeptidases; Snake venom-like protease; TNF-alpha convertase; TNF-alpha converting enzyme; TNF-alpha-converting enzyme; tumor necrosis factor, alpha, converting enzyme
Gene Aliases: ADAM17; ADAM18; CD156B; CSVP; NISBD; NISBD1; TACE
UniProt ID: (Human) P78536
Entrez Gene ID: (Human) 6868